CN109983032A - Tim-3抗体、其抗原结合片段及医药用途 - Google Patents

Tim-3抗体、其抗原结合片段及医药用途 Download PDF

Info

Publication number
CN109983032A
CN109983032A CN201880004331.9A CN201880004331A CN109983032A CN 109983032 A CN109983032 A CN 109983032A CN 201880004331 A CN201880004331 A CN 201880004331A CN 109983032 A CN109983032 A CN 109983032A
Authority
CN
China
Prior art keywords
antibody
seq
antigen
binding fragment
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201880004331.9A
Other languages
English (en)
Other versions
CN109983032B (zh
Inventor
曹卓晓
付雅媛
张婷
陶维康
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Publication of CN109983032A publication Critical patent/CN109983032A/zh
Application granted granted Critical
Publication of CN109983032B publication Critical patent/CN109983032B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4725—Mucins, e.g. human intestinal mucin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

本发明提供了TIM‑3抗体、其抗原结合片段及医药用途。进一步地，本发明提供了包含所述TIM‑3抗体CDR区的鼠源抗体、嵌合抗体、人源化抗体，以及包含TIM‑3抗体及其抗原结合片段的药物组合物，以及其作为药物的用途。特别地，本发明提供了一种人源化的TIM‑3抗体在制备用于治疗TIM‑3相关的疾病或病症的药物中的用途。

Description

PCT国内申请，说明书已公开。

Claims (30)

  1. PCT国内申请，权利要求书已公开。
CN201880004331.9A 2017-02-27 2018-02-26 Tim-3抗体、其抗原结合片段及医药用途 Active CN109983032B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2017101087472 2017-02-27
CN201710108747 2017-02-27
PCT/CN2018/077190 WO2018153366A1 (zh) 2017-02-27 2018-02-26 Tim-3抗体、其抗原结合片段及医药用途

Publications (2)

Publication Number Publication Date
CN109983032A true CN109983032A (zh) 2019-07-05
CN109983032B CN109983032B (zh) 2022-07-26

Family

ID=63254208

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880004331.9A Active CN109983032B (zh) 2017-02-27 2018-02-26 Tim-3抗体、其抗原结合片段及医药用途

Country Status (6)

Country Link
US (1) US11345753B2 (zh)
EP (1) EP3587452A4 (zh)
JP (1) JP2020508658A (zh)
CN (1) CN109983032B (zh)
TW (1) TW201831512A (zh)
WO (1) WO2018153366A1 (zh)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112094348A (zh) * 2020-09-22 2020-12-18 首都医科大学附属北京胸科医院 抗人Tim3抗体或其功能性片段及其应用
CN112512582A (zh) * 2018-08-20 2021-03-16 江苏恒瑞医药股份有限公司 Tim-3抗体在制备治疗肿瘤的药物中的用途
CN112543647A (zh) * 2018-08-28 2021-03-23 江苏恒瑞医药股份有限公司 一种tim3抗体药物组合物及其用途

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230279105A1 (en) * 2019-06-21 2023-09-07 Single Cell Technology, Inc. Anti-tim-3 antibodies
WO2021051352A1 (zh) * 2019-09-19 2021-03-25 上药生物治疗（香港）有限公司 一种分离的抗原结合蛋白及其用途
EP4326773A1 (en) * 2021-04-23 2024-02-28 Suzhou Neologics Bioscience Co., Ltd. Tim-3-targetting antibodies and uses thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102492038A (zh) * 2011-12-09 2012-06-13 中国人民解放军军事医学科学院基础医学研究所 抗人Tim-3的中和性单克隆抗体L3D及其用途
CN103079644A (zh) * 2010-06-11 2013-05-01 协和发酵麒麟株式会社 抗tim-3抗体
CN104592388A (zh) * 2015-03-02 2015-05-06 中国人民解放军总医院 一种抗人Tim-3的单克隆抗体的抗原结合部分
US20160200815A1 (en) * 2015-01-05 2016-07-14 Jounce Therapeutics, Inc. Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
CN106132991A (zh) * 2014-01-31 2016-11-16 诺华股份有限公司 针对tim‑3的抗体分子及其用途
WO2017019897A1 (en) * 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to tim-3

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
CA2802344C (en) 2010-06-18 2023-06-13 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
US8841418B2 (en) 2011-07-01 2014-09-23 Cellerant Therapeutics, Inc. Antibodies that specifically bind to TIM3
JP2018510151A (ja) 2015-03-06 2018-04-12 ソレント・セラピューティクス・インコーポレイテッド Ｔｉｍ３に結合する抗体医薬
MA41867A (fr) 2015-04-01 2018-02-06 Anaptysbio Inc Anticorps dirigés contre l'immunoglobuline de cellule t et protéine 3 de mucine (tim-3)

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103079644A (zh) * 2010-06-11 2013-05-01 协和发酵麒麟株式会社 抗tim-3抗体
CN102492038A (zh) * 2011-12-09 2012-06-13 中国人民解放军军事医学科学院基础医学研究所 抗人Tim-3的中和性单克隆抗体L3D及其用途
CN106132991A (zh) * 2014-01-31 2016-11-16 诺华股份有限公司 针对tim‑3的抗体分子及其用途
US20160200815A1 (en) * 2015-01-05 2016-07-14 Jounce Therapeutics, Inc. Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
CN104592388A (zh) * 2015-03-02 2015-05-06 中国人民解放军总医院 一种抗人Tim-3的单克隆抗体的抗原结合部分
WO2017019897A1 (en) * 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to tim-3

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DAS,MADHUMITA等: "Tim-3 and its role in regulating anti-tumor immunity", 《IMMUNOLOGICAL REVIEWS》 *
NDHLOVU,LC等: "Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity", 《BLOOD》 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112512582A (zh) * 2018-08-20 2021-03-16 江苏恒瑞医药股份有限公司 Tim-3抗体在制备治疗肿瘤的药物中的用途
CN112512582B (zh) * 2018-08-20 2024-04-16 江苏恒瑞医药股份有限公司 Tim-3抗体在制备治疗肿瘤的药物中的用途
CN112543647A (zh) * 2018-08-28 2021-03-23 江苏恒瑞医药股份有限公司 一种tim3抗体药物组合物及其用途
CN112543647B (zh) * 2018-08-28 2024-04-16 江苏恒瑞医药股份有限公司 一种tim3抗体药物组合物及其用途
CN112094348A (zh) * 2020-09-22 2020-12-18 首都医科大学附属北京胸科医院 抗人Tim3抗体或其功能性片段及其应用

Also Published As

Publication number Publication date
TW201831512A (zh) 2018-09-01
EP3587452A4 (en) 2021-03-03
CN109983032B (zh) 2022-07-26
WO2018153366A1 (zh) 2018-08-30
US20190375839A1 (en) 2019-12-12
EP3587452A1 (en) 2020-01-01
US11345753B2 (en) 2022-05-31
JP2020508658A (ja) 2020-03-26

Similar Documents

Publication Publication Date Title
KR102497259B1 (ko) Ｌａｇ―３ 항체, 이의 항원-결합 단편 및 이의 약학적 용도
JP7317272B2 (ja) Ｔｉｇｉｔ抗体、その抗原結合断片及びその医療用途 本願は、２０１９年９月２９日に出願された出願番号ｃｎ２０１７１０９０８５６５．３に基づいたものであり、その優先権を主張する。その開示は、その全体が参照により本明細書に組み込まれる。
CN109937212B (zh) B7-h3抗体、其抗原结合片段及其医药用途
WO2018095428A1 (zh) Cd47抗体、其抗原结合片段及其医药用途
CN110366560B (zh) 抗b7-h4抗体、其抗原结合片段及其医药用途
CN109983032A (zh) Tim-3抗体、其抗原结合片段及医药用途
US20160376367A1 (en) Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
EP3712170A1 (en) Cd96 antibody, antigen-binding fragment and pharmaceutical use thereof
CN109843927A (zh) 抗b7-h3抗体、其抗原结合片段及其医药用途
CN110267989A (zh) 抗cd40抗体、其抗原结合片段及其医药用途
JP2021506922A (ja) Ｌａｇ−３抗体医薬組成物およびその使用
CN107531797A (zh) 凝血酶抗体、其抗原结合片段及医药用途
TWI685504B (zh) 抗gitr抗體、其抗原結合片段及其醫藥用途
CN108178798A (zh) pH工程化的NGF抗体及其医药用途
CN112543647B (zh) 一种tim3抗体药物组合物及其用途
WO2019238074A1 (zh) 一种高亲和力高生物活性的lag-3抗体及其应用
AU2021223128A1 (en) Pharmaceutical composition containing anti-IL-4R antibody and use thereof
CN115947855B (zh) 抗cd24抗体的制备及其用途
RU2737466C1 (ru) Гуманизированное нейтрализующее антитело к интерферону-бета человека

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40009318

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant